Related Experiment Videos
Overview: treatment of cryptococcal meningitis
A M Sugar1, J J Stern, B Dupont
1Evans Memorial Department of Clinical Research, Boston University Medical Center, Massachusetts.
Abstract:
Infections caused by Cryptococcus neoformans cause significant morbidity and high mortality, particularly among immunocompromised patients. Cryptococcal meningitis is an important cause of central nervous system disease and death in patients with AIDS. Although the introduction of amphotericin B has greatly improved the prognosis of patients with cryptococcal meningitis, 30 years of experience have revealed important clinical limitations, including modest efficacy, nephrotoxicity, other clinically significant toxicities, and the inconvenience of intravenous dosing. The discovery of the additive effects of amphotericin B and flucytosine in cryptococcosis resulted in some improvement in efficacy and reduction in amphotericin B-related toxicity. However, approximately 30% of patients with cryptococcal meningitis still fail to respond to therapy. Ketoconazole has not proved useful in treating cryptococcal meningitis. Accumulating evidence suggests that the antifungal triazoles fluconazole, itraconazole, and SCH 39304 represent an advance in the treatment of cryptococcal meningitis, particularly in AIDS patients. Preliminary clinical trials in patients with and without AIDS have indicated that fluconazole and intraconazole are effective and well tolerated as either initial or maintenance therapy. Two large comparative trials of fluconazole and amphotericin B in patients with cryptococcal meningitis (mostly those with AIDS) are under way.
Insights
New antifungal triazoles like fluconazole show promise for treating cryptococcal meningitis, offering better options than older drugs for immunocompromised patients. These agents are effective and well-tolerated, improving patient outcomes.
Area of Science:
- Mycology
- Infectious Diseases
- Pharmacology
Background:
- Cryptococcus neoformans infections, especially meningitis, cause significant mortality in immunocompromised individuals, notably those with AIDS.
- Amphotericin B, while improving prognosis, has limitations including modest efficacy, toxicity, and IV administration.
- Current therapies like amphotericin B and flucytosine have a ~30% failure rate; ketoconazole is ineffective.
Purpose of the Study:
- To evaluate the efficacy and tolerability of newer antifungal agents for cryptococcal meningitis.
- To identify improved treatment options beyond traditional therapies for this serious infection.
Main Methods:
- Review of accumulating evidence and preliminary clinical trials.
- Assessment of antifungal triazoles including fluconazole, itraconazole, and SCH 39304.
- Comparison of newer agents with established treatments like amphotericin B.
Main Results:
- Antifungal triazoles (fluconazole, itraconazole) show effectiveness and good tolerability in preliminary trials.
- These agents are suitable for both initial and maintenance therapy in cryptococcal meningitis patients, including those with AIDS.
- Ongoing large comparative trials are evaluating fluconazole against amphotericin B.
Conclusions:
- Antifungal triazoles represent a significant advancement in treating cryptococcal meningitis.
- Fluconazole and itraconazole offer a well-tolerated and effective alternative for managing this opportunistic infection.
- Further research through comparative trials will solidify the role of these agents in clinical practice.